Vigabatrin absorption is mediated via the proton-coupled amino acid transporter PAT1 – in vitro and in vivo

TY - CONF

T1 - Vigabatrin absorption is mediated via the proton-coupled amino acid transporter PAT1 – in vitro and in vivo

AU - Nøhr, Martha Kampp

AU - Juul, Rasmus Vestergaard

AU - Hansen, Steen Honore'

AU - Brodin, Birger

AU - Holm, René

AU - Kreilgaard, Mads

AU - Nielsen, Carsten Uhd

PY - 2013/6/24

Y1 - 2013/6/24

N2 - Purpose The anti-epileptic drug substance vigabatrin is used mainly for the treatment of infantile spasms. In spite of its hydrophilic nature (LogD7.0 ; -2.16), vigabatrin is readily absorbed after oral administration to humans. Vigabatrin has been shown in vitro to be a substrate of the intestinal proton coupled amino acid transporter PAT1, however the actual transport mechanisms involved in transepithelial absorption have not been clarified. The aim of the study was to investigate whether the transepithelial absorption of vigabatrin is mediated by PAT1 – in vitro as well as in vivo. Methods The absorption of vigabatrin was investigated using Caco-2 cell monolayers and Sprague Dawley rats as an in vitro and in vivo model, respectively. LC-MS or LC-MS/MS was applied for the quantification.Results The permeability of vigabatrin in Caco-2 cell monolayers was increased at apical pH 6.0 compared to pH 7.4. The transepithelial transport across Caco-2 cell monolayers was polarized in the lumen-to-blood direction in the presence of a proton gradient. The presence of PAT1-ligands significantly decreased the permeability of vigabatrin across Caco-2 cell monolayers. In Sprague Dawley rats the presence of PAT1-ligands altered the pharmacokinetic profile of vigabatrin with an apparent prolonged absorption of vigabatrin.ConclusionsTransport of vigabatrin across Caco-2 cell monolayers was polarized in the lumen-to-blood directions, dependent on an acidic pH in the lumen compartment and inhibited by PAT1-ligands. This indicated that PAT1 was the apical entry step in the transepithelial transport pathway. This was supported by in vivo findings, showing that inhibition of PAT1 prolonged the absorption phase of vigabatrin. It is, hence, concluded that PAT1 is involved in vigabatrin transport both in vitro and in vivo.

AB - Purpose The anti-epileptic drug substance vigabatrin is used mainly for the treatment of infantile spasms. In spite of its hydrophilic nature (LogD7.0 ; -2.16), vigabatrin is readily absorbed after oral administration to humans. Vigabatrin has been shown in vitro to be a substrate of the intestinal proton coupled amino acid transporter PAT1, however the actual transport mechanisms involved in transepithelial absorption have not been clarified. The aim of the study was to investigate whether the transepithelial absorption of vigabatrin is mediated by PAT1 – in vitro as well as in vivo. Methods The absorption of vigabatrin was investigated using Caco-2 cell monolayers and Sprague Dawley rats as an in vitro and in vivo model, respectively. LC-MS or LC-MS/MS was applied for the quantification.Results The permeability of vigabatrin in Caco-2 cell monolayers was increased at apical pH 6.0 compared to pH 7.4. The transepithelial transport across Caco-2 cell monolayers was polarized in the lumen-to-blood direction in the presence of a proton gradient. The presence of PAT1-ligands significantly decreased the permeability of vigabatrin across Caco-2 cell monolayers. In Sprague Dawley rats the presence of PAT1-ligands altered the pharmacokinetic profile of vigabatrin with an apparent prolonged absorption of vigabatrin.ConclusionsTransport of vigabatrin across Caco-2 cell monolayers was polarized in the lumen-to-blood directions, dependent on an acidic pH in the lumen compartment and inhibited by PAT1-ligands. This indicated that PAT1 was the apical entry step in the transepithelial transport pathway. This was supported by in vivo findings, showing that inhibition of PAT1 prolonged the absorption phase of vigabatrin. It is, hence, concluded that PAT1 is involved in vigabatrin transport both in vitro and in vivo.

M3 - Poster

ER -